Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | COMT | P21964 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272695 | 1.00 | KDM4E (0.49) | KDM4EUSP2COMTGABRA1GABRG2 | |
| SCHEMBL25224357 | 0.81 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL3272752 | 0.81 | MAPK14 (0.43) | KDM4EMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6771371 | 0.77 | SRC (0.62) | KDM4EUSP2MAPK14NPC1MAPK13 | |
| SCHEMBL19927502 | 0.76 | PTGS2 (0.54) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL3277198 | 0.76 | KDM4E (0.51) | KDM4EUSP2COMTGABRA1GABRG2 | |
| SCHEMBL25269369 | 0.74 | MAPK14 (0.61) | KDM4EMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14619167 | 0.74 | MAPT (0.51) | KDM4ENPC1RAB9A | |
| SCHEMBL29733664 | 0.74 | KDM4E (0.71) | KDM4EUSP2NPC1KDRRAB9A | |
| SCHEMBL4094356 | 0.74 | KDM4E (0.71) | KDM4EUSP2NPC1KDRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825254-B2 | Heteroaromatic quinoline compounds | PFIZER INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1841757-B1 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PROD INC (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7429665-B2 | Heteroaromatic quinoline compounds | PFIZER INC (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PFIZER INC | 2008-09-04 | — | — | US | disclosed |
| EP-1841757-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Pfizer Products Incorporated (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PFIZER INC | 2006-07-13 | — | — | US | disclosed |
| WO-2006072828-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PDE12, PDE7A, PDE4A | KDM4E 1059/4885USP2 1864/4885COMT 35/4885 |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PDE12, PDE7A, PDE4A | KDM4E 1059/4885USP2 1864/4885COMT 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.